BPC-157

Clinical maturity: Preclinical, with very limited early human study activity

Regulatory material describes products marketed as injections, nasal sprays and oral capsules. That is a description of the unregulated market, not evidence that any route works or is safe. No approved formulation exists for any route.

Route availability is not evidence of efficacy, and evidence from one route does not transfer to another. The Registry never provides dosing or sourcing information.

A synthetic 15-amino-acid sequence derived from a protein found in gastric juice. It has been studied for decades in rodents across an unusually wide range of injury models.

• Heals tendons, ligaments and muscle tears
• Repairs the gut lining and helps IBD
• Reduces inflammation and speeds recovery from almost anything

The preclinical literature is large, consistent and mostly produced by a small number of related research groups. The human literature is close to empty: no adequately powered, published, randomised controlled trial supports the tendon and injury-recovery claims that dominate online discussion. Enthusiastic rodent results plus enthusiastic forum posts do not add up to clinical evidence.

• No adequately powered published randomised controlled trials supporting musculoskeletal healing claims.
• Limited early-phase clinical activity historically explored in inflammatory bowel disease; results have not established efficacy.
• Everything else circulating is anecdote (Level 0).

• Numerous rodent studies reporting accelerated tendon, ligament, muscle and gut healing.
• Reported protective effects against NSAID-induced gastrointestinal injury in animals.
• Concentration of output within a small research network is a replication concern, not a conspiracy claim — independent replication is simply thin.

Animal and cell findings are Level 1–2 evidence.

• Proposed upregulation of VEGF signalling and angiogenesis at injury sites.
• Interaction with nitric oxide pathways.
• Proposed effects on growth-hormone receptor expression in tendon fibroblasts.
• All of this is mechanistic (Level 1-2) and does not establish clinical benefit.

• No systematic human safety dataset exists. Absence of reported harm is not evidence of safety.
• The FDA's 503A Category 2 listing flags significant safety risks for compounding — a regulatory safety concern, not proof of harm in any individual.
• Product quality is a real and separate risk: unapproved supply chains have documented issues with purity, sterility and mislabelling.
• Because it is injected by non-clinicians in most real-world use, infection and technique risks are underappreciated.

Not an approved medicine in any major region. The FDA has placed BPC-157 on the 503A Category 2 list of bulk substances that raise significant safety risks for compounding, which restricts its use in compounded preparations. It remains widely sold as a 'research chemical'.

• Baseline · United States

  Placed on the FDA 503A Category 2 list of bulk substances raising significant safety risks for compounding; not an approved medicine in any major region.

• L2PreclinicalRodent tendon and gut injury models

  Preclinical animal studies — Rats and mice

  Consistent healing effects in animals; concentrated within a small research network.

• A published, adequately powered randomised controlled trial in a defined injury population.
• Independent replication of core preclinical findings outside the originating research network.
• Any published human pharmacokinetic and safety dataset.

• Regulatory / labelFDA — Bulk drug substances used in compounding (Category 2: significant safety risks)

Source hierarchy: regulatory documents and trial registries first, peer-reviewed work next, sponsor material flagged as non-independent. We never use supplier or clinic marketing as evidence, and where a verified source has not yet been curated we say so rather than inventing one.

1. 2026-07-10

   Baseline entry: registry position set to preclinical-only for musculoskeletal healing claims.

   L2PreclinicalBaseline entry
   Reviewed the available literature landscape. Preclinical breadth is large; controlled human evidence for tendon and injury claims remains absent, so confidence stays very low.